Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 332.2% in February

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 228,200 shares, an increase of 332.2% from the February 13th total of 52,800 shares. Based on an average daily volume of 354,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 4.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.62% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission. 49.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price target on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, December 16th.

Alzamend Neuro Price Performance

Shares of Alzamend Neuro stock opened at $0.67 on Thursday. Alzamend Neuro has a 52-week low of $0.66 and a 52-week high of $15.06. The firm has a 50-day moving average of $1.04 and a 200-day moving average of $1.40.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. As a group, equities analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.